Clinical utilities and biological characteristics of melanoma sentinel lymph nodes

Dale Han, Daniel C. Thomas, Jonathan S. Zager, Barbara A Pockaj, Richard L. White, Stanley P L Leong

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

An estimated 73870 people will be diagnosed with melanoma in the United States in 2015, resulting in 9940 deaths. The majority of patients with cutaneous melanomas are cured with wide local excision. However, current evidence supports the use of sentinel lymph node biopsy (SLNB) given the 15%-20% of patients who harbor regional node metastasis. More importantly, the presence or absence of nodal micrometastases has been found to be the most important prognostic factor in earlystage melanoma, particularly in intermediate thickness melanoma. This review examines the development of SLNB for melanoma as a means to determine a patient' s nodal status, the efficacy of SLNB in patients with melanoma, and the biology of melanoma metastatic to sentinel lymph nodes. Prospective randomized trials have guided the development of practice guidelines for use of SLNB for melanoma and have shown the prognostic value of SLNB. Given the rapidly advancing molecular and surgical technologies, the technical aspects of diagnosis, identification, and management of regional lymph nodes in melanoma continues to evolve and to improve. Additionally, there is ongoing research examining both the role of SLNB for specific clinical scenarios and the ways to identify patients who may benefit from completion lymphadenectomy for a positive SLN. Until further data provides sufficient evidence to alter national consensusbased guidelines, SLNB with completion lymphadenectomy remains the standard of care for clinically node-negative patients found to have a positive SLN.

Original languageEnglish (US)
Pages (from-to)174-188
Number of pages15
JournalWorld Journal of Clinical Oncology
Volume7
Issue number2
DOIs
StatePublished - Apr 10 2016

Fingerprint

Sentinel Lymph Node Biopsy
Melanoma
Lymph Node Excision
Sentinel Lymph Node
Neoplasm Micrometastasis
Standard of Care
Practice Guidelines
Lymph Nodes
Guidelines
Neoplasm Metastasis
Technology
Skin
Research

Keywords

  • Biologic characteristics
  • Melanoma
  • Metastasis
  • Review
  • Sentinel lymph node
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. / Han, Dale; Thomas, Daniel C.; Zager, Jonathan S.; Pockaj, Barbara A; White, Richard L.; Leong, Stanley P L.

In: World Journal of Clinical Oncology, Vol. 7, No. 2, 10.04.2016, p. 174-188.

Research output: Contribution to journalArticle

Han, Dale ; Thomas, Daniel C. ; Zager, Jonathan S. ; Pockaj, Barbara A ; White, Richard L. ; Leong, Stanley P L. / Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. In: World Journal of Clinical Oncology. 2016 ; Vol. 7, No. 2. pp. 174-188.
@article{1191f9b02d394387a765a3058601e51c,
title = "Clinical utilities and biological characteristics of melanoma sentinel lymph nodes",
abstract = "An estimated 73870 people will be diagnosed with melanoma in the United States in 2015, resulting in 9940 deaths. The majority of patients with cutaneous melanomas are cured with wide local excision. However, current evidence supports the use of sentinel lymph node biopsy (SLNB) given the 15{\%}-20{\%} of patients who harbor regional node metastasis. More importantly, the presence or absence of nodal micrometastases has been found to be the most important prognostic factor in earlystage melanoma, particularly in intermediate thickness melanoma. This review examines the development of SLNB for melanoma as a means to determine a patient' s nodal status, the efficacy of SLNB in patients with melanoma, and the biology of melanoma metastatic to sentinel lymph nodes. Prospective randomized trials have guided the development of practice guidelines for use of SLNB for melanoma and have shown the prognostic value of SLNB. Given the rapidly advancing molecular and surgical technologies, the technical aspects of diagnosis, identification, and management of regional lymph nodes in melanoma continues to evolve and to improve. Additionally, there is ongoing research examining both the role of SLNB for specific clinical scenarios and the ways to identify patients who may benefit from completion lymphadenectomy for a positive SLN. Until further data provides sufficient evidence to alter national consensusbased guidelines, SLNB with completion lymphadenectomy remains the standard of care for clinically node-negative patients found to have a positive SLN.",
keywords = "Biologic characteristics, Melanoma, Metastasis, Review, Sentinel lymph node, Sentinel lymph node biopsy",
author = "Dale Han and Thomas, {Daniel C.} and Zager, {Jonathan S.} and Pockaj, {Barbara A} and White, {Richard L.} and Leong, {Stanley P L}",
year = "2016",
month = "4",
day = "10",
doi = "10.5306/wjco.v7.i2.174",
language = "English (US)",
volume = "7",
pages = "174--188",
journal = "World Journal of Clinical Oncology",
issn = "2218-4333",
publisher = "Baishideng Publishing Group",
number = "2",

}

TY - JOUR

T1 - Clinical utilities and biological characteristics of melanoma sentinel lymph nodes

AU - Han, Dale

AU - Thomas, Daniel C.

AU - Zager, Jonathan S.

AU - Pockaj, Barbara A

AU - White, Richard L.

AU - Leong, Stanley P L

PY - 2016/4/10

Y1 - 2016/4/10

N2 - An estimated 73870 people will be diagnosed with melanoma in the United States in 2015, resulting in 9940 deaths. The majority of patients with cutaneous melanomas are cured with wide local excision. However, current evidence supports the use of sentinel lymph node biopsy (SLNB) given the 15%-20% of patients who harbor regional node metastasis. More importantly, the presence or absence of nodal micrometastases has been found to be the most important prognostic factor in earlystage melanoma, particularly in intermediate thickness melanoma. This review examines the development of SLNB for melanoma as a means to determine a patient' s nodal status, the efficacy of SLNB in patients with melanoma, and the biology of melanoma metastatic to sentinel lymph nodes. Prospective randomized trials have guided the development of practice guidelines for use of SLNB for melanoma and have shown the prognostic value of SLNB. Given the rapidly advancing molecular and surgical technologies, the technical aspects of diagnosis, identification, and management of regional lymph nodes in melanoma continues to evolve and to improve. Additionally, there is ongoing research examining both the role of SLNB for specific clinical scenarios and the ways to identify patients who may benefit from completion lymphadenectomy for a positive SLN. Until further data provides sufficient evidence to alter national consensusbased guidelines, SLNB with completion lymphadenectomy remains the standard of care for clinically node-negative patients found to have a positive SLN.

AB - An estimated 73870 people will be diagnosed with melanoma in the United States in 2015, resulting in 9940 deaths. The majority of patients with cutaneous melanomas are cured with wide local excision. However, current evidence supports the use of sentinel lymph node biopsy (SLNB) given the 15%-20% of patients who harbor regional node metastasis. More importantly, the presence or absence of nodal micrometastases has been found to be the most important prognostic factor in earlystage melanoma, particularly in intermediate thickness melanoma. This review examines the development of SLNB for melanoma as a means to determine a patient' s nodal status, the efficacy of SLNB in patients with melanoma, and the biology of melanoma metastatic to sentinel lymph nodes. Prospective randomized trials have guided the development of practice guidelines for use of SLNB for melanoma and have shown the prognostic value of SLNB. Given the rapidly advancing molecular and surgical technologies, the technical aspects of diagnosis, identification, and management of regional lymph nodes in melanoma continues to evolve and to improve. Additionally, there is ongoing research examining both the role of SLNB for specific clinical scenarios and the ways to identify patients who may benefit from completion lymphadenectomy for a positive SLN. Until further data provides sufficient evidence to alter national consensusbased guidelines, SLNB with completion lymphadenectomy remains the standard of care for clinically node-negative patients found to have a positive SLN.

KW - Biologic characteristics

KW - Melanoma

KW - Metastasis

KW - Review

KW - Sentinel lymph node

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=84963811555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963811555&partnerID=8YFLogxK

U2 - 10.5306/wjco.v7.i2.174

DO - 10.5306/wjco.v7.i2.174

M3 - Article

VL - 7

SP - 174

EP - 188

JO - World Journal of Clinical Oncology

JF - World Journal of Clinical Oncology

SN - 2218-4333

IS - 2

ER -